RPCK advised the sports and biotech start-up Biolyz FlexCo, which specialises in performance diagnostics using saliva analysis, on an investment round “in a significant seven-figure amount”.

RPCK has been advising Biolyz since its foundation in 2021. The start-up has since specialised in machine learning-based analyses of non-invasively measurable biomarkers. This is intended to help competitive athletes in particular to perform better and enjoy a longer professional life in sport.

The investment was made for the first time by utilising authorised capital (see FlexCo highlights here).

Read more about Biolyz and the transaction here.